Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: Does Helicobacter pylori infection affect proton pump inhibitor effectiveness?

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 4, 2004, Pages 451-458

  De Wit, N J ^a   De Boer, W A ^b   Geldof, H ^c   Hazelhoff, B ^d   Bergmans, P ^d   Tytgat, G N J ^e   Smout, A J P M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b BERNHOVEN HOSPITAL   (Netherlands)

^c IJSSELLAND HOSPITAL   (Netherlands)

^d Janssen Cilag BV Netherlands   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTI-ULCER AGENTS; BENZIMIDAZOLES; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; TREATMENT OUTCOME;

EID: 4344689146     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02096.x     Document Type: Article

References (32)

1. Johanson JF. Epidemiology of esophageal and supraesophageal reflux injuries. Am J Med 2000; 108: 99s-103s.
2. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
3. Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991; 26: 73-81.
4. Kennedy T, Jones R. The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000; 14: 1589-94.
5. Jones R. Gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1995; 211 (Suppl.): 35-8.
6. Dent J, Jones R, Kahrilas P, Talley NJ. Management of gastrooesophageal reflux disease in general practice. BMJ 2001; 322: 344-7.
7. Van Pinxteren B, Numans ME, De Wit NJ, Hungin AP, Lau J, Bonis PA. Short term treatment of gastroesophageal reflux disease: a meta-analysis. J Gen Int Med 2003; 18: 755-63.
8. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 266-80.
9. Glasbrenner B, Malfertheiner P, Nilius M, et al. Prevalence of Helicobacter pylori infection and dyspepsia in young adults in Germany. Z Gastroenterol 1996; 34: 478-82.
10. DeWit NJ, Mendive J, Seifert B, Cardin F, Rubin G. Guidelines on the management of H. pylori in primary care: development of an implementation strategy. Fam Pract 2000; 17 (Suppl. 2): S27-32.
11. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003; 326: 737.
12. Lundell L. Gastro-oesophageal reflux disease and Helicobacter pylori or gastro-oesophageal reflux disease from Helicobacter pylori? Eur J Gastroenterol Hepatol 2001; 13 (Suppl. 1): 23-7 (Review).
13. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 45-51.
14. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112: 1442-7.
15. Malfertheiner P, Bayerdorffer E, Diete U, et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-12.
16. Williams MP, Usselmann B, Chilton A, Sercombe J, Nwokolo CU, Pounder RE. Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo. Aliment Pharmacol Ther 2003; 17: 775-83.
17. Verdú BF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
18. Van Herwaarden MA, Samsom M, Van Nispen CHM, Mulder PGH, Smout AJPM. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999; 13: 731-40.
19. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
20. Hattlebakk JG, Hyggen A, Madsen PH, et al. Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ 1999; 319: 550-53.
21. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SG. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 884-7.
22. Hattlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. Aliment Pharmacol Ther 1997; 11: 1093-9.
23. Schwizer W, Thumshirn M, Dent J, et al. Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial. Lancet 2001; 357: 1738-42.
24. Numans ME, De Wit NJ. Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire. Aliment Pharmacol Ther 2003; 17: 1049-55.
25. Van der Ende A, Van der Hulst RW, Roorda P, Tytgat GN, Dankert J. Evaluation of three commercial serological tests with different methodologies to assess Helicobacter pylori infection. J Clin Microbiol 1999; 37: 4150-2.
26. Dupuy HJ. The Psychological General Well-being (PGWB) Index. In: Wenger NK, Mattson ME, Furberg CF, Elinson J, ed. Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies. New York: Le Jacq Publishing, 1984: 170-83.
27. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 221: 8-13.
28. Bijkerk R, Muris R, Hoes AW, Jones RJ, Knottnerus A, De Wit NJ. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2000; 98: 122-7.
29. Shaw M, Talley NJ, Adlis S, Beebe T, Tomshine P, Healy M. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. Aliment Pharmacol Ther 1998; 12: 1067-78.
30. Chey WD, Olden K, Carter E, Boyle J, Drossman D, Chang L. Utility of the Rome I and II criteria for irritable bowel syndrome in US woman. Am J Gastroenterol 2002; 97: 2803-11.
31. Robinson S, Fitzgerald R, Hegedus R, Murthy A, Jokubaitis L. Onset of symptom relief with rabeprazole: a community-based open-label assessment of patients with erosive oesophagitis. Aliment Pharmacol Ther 2002; 16: 445-54.
32. Quigley EM, Dibaise JK. Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease. Dig Liver Dis 2001; 33: 523-7.